Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a ...

Q1 2025 Management View CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, ...

Recursion and Sanofi advanced their fourth partnered program through a significant discovery milestone. This milestone involved the Recursion OS identifying differentiated, orally active small ...

In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and ...